Stockscreener 앱 받기
0.6201
3.71%
-0.024
전일 마감가:
$0.6441
열려 있는:
$0.6369
하루 거래량:
701.34K
Relative Volume:
0.39
시가총액:
$16.69M
수익:
-
순이익/손실:
$-23.36M
주가수익비율:
-0.8416
EPS:
-0.7368
순현금흐름:
-
1주 성능:
-18.50%
1개월 성능:
-49.16%
6개월 성능:
-61.24%
1년 성능:
-92.83%
1일 변동 폭
$0.58
$0.6483
1주일 범위
$0.58
$0.78
52주 변동 폭
$0.58
$16.80
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
명칭
Calidi Biotherapeutics Inc
전화
(858) 794-9600
주소
4475 Executive Drive, Suite 200, San Diego
CLDI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
0.6202 | 16.69M | 0 | -23.36M | 0 | -0.7368 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.19 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.43 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
662.88 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.25 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.25 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-22 | 개시 | H.C. Wainwright | Buy |
| 2023-10-09 | 개시 | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc 주식(CLDI)의 최신 뉴스
CLDI Stock Plummets to 52-Week Low at $0.6 Amid Market Turbulence - Investing.com
Calidi Biotherapeutics Bolsters Cash Balance and Terminates Standby Equity Purchase AgreementSAN DIEGO, January 28, 2025 – Calidi Biotherapeutics Inc. (NYSE American: CLDI) recently disclosed the ending cash balance amounting to approximately $ - Defense World
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5 - The Manila Times
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5 - GlobeNewswire
Inside Calidi's Game-Changing Cancer Treatment Pipeline: Top Execs Reveal Next-Gen Therapies - StockTitan
CLDICalidi Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Calidi Biotherapeutics Ends SEPA After Successful Fundraising - TipRanks
Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement - GlobeNewswire
Cancer Biotech Raises $18.8M War Chest to Fast-Track Revolutionary Brain Cancer Treatment - StockTitan
Why Calidi Biotherapeutics Inc (AMEX: CLDI) Is A Great Stock Pick For Momentum Investors - Stocks Register
CLDI stock touches 52-week low at $0.73 amid market challenges - MSN
The Business Case For Buying Calidi Biotherapeutics Inc (AMEX: CLDI) Stock Now - Stocks Register
Calidi Biotherapeutics Announces Presentation of New Data - GlobeNewswire
Calidi Biotherapeutics to Present Breakthrough Cancer Treatment Platform at AACR 2025 Meeting - StockTitan
Calidi Biotherapeutics announces reverse stock split adjustment - Investing.com
Calidi Biotherapeutics Inc (CLDI-A) QuotePress Release - The Globe and Mail
Calidi Biotherapeutics Announces $4.25 Million Public Stock Offering - Defense World
Calidi Biotherapeutics Refiles Consolidated Financial Statements After Reverse Stock Split - Defense World
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock - The Bakersfield Californian
Calidi Biotherapeutics Raises $4.25M Through Public Offering of Common Stock at $0.85 Per Share - StockTitan
Why Calidi Biotherapeutics (CLDI) Stock Is Down 30% - Benzinga
Calidi Biotherapeutics slumps 29%, prices $4.25M stock offering - MSN
Calidi Biotherapeutics Announces Public Stock Offering Deal - TipRanks
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock - The Bakersfield Californian
Calidi Biotherapeutics Raises $4.25M Through Public Offering to Advance Cancer Immunotherapy Platform - StockTitan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Calidi Biotherapeutics (NYSE:CLDI) Stock Price Down 8.2% – Should You Sell? - Defense World
Calidi Biotherapeutics Announces Proposed Public Offering - The Manila Times
Calidi Biotherapeutics Announces Common Stock Public Offering to Advance Immunotherapy Pipeline - StockTitan
Reviewing Calidi Biotherapeutics (NYSE:CLDI) & iTeos Therapeutics (NASDAQ:ITOS) - Defense World
Comparing Calidi Biotherapeutics (NYSE:CLDI) & Immatics (NASDAQ:IMTX) - Defense World
Calidi Biotherapeutics CEO Allan Camaisa sells $16,200 in stock - Investing.com India
Calidi Biotherapeutics prices $7.5M secondary offering - MSN
Calidi Biotherapeutics (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer Care - Barchart
UMACUnusual Machines, Inc. Latest Stock News & Market Updates - StockTitan
Calidi Biotherapeutics (NYSE American: CLDI) Shares Data Supporting Proprietary Systemic Antitumor Platform - Barchart
Calidi Biotherapeutics announces pricing of $7.5M public offering of common stock - MSN
Calidi Biotherapeutics (NYSE American: CLDI) Raises $7.5 Million Through Public Stock Offering - Barchart
If You Don’t Buy Calidi Biotherapeutics Inc (AMEX: CLDI) Now, You’ll Kick Yourself Later - Stocks Register
Calidi Biotherapeutics Reveals Promising Virotherapy Data - TipRanks
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer - EIN News
Calidi presents data on RTNova systemic technology in metastatic lung cancer - TipRanks
Calidi Bio's RTNova Shows Promise in Metastatic Lung Cancer Treatment Breakthrough | CLDI Stock News - StockTitan
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock - The Manila Times
Calidi Biotherapeutics Raises $7.5M Through Public Offering of 4.4M Shares | CLDI Stock News - StockTitan
Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews
SEC Form 424B5 filed by Calidi Biotherapeutics Inc. - Quantisnow
Calidi prices 4.4M shares at $1.69 in public offering - TipRanks
Calidi Biotherapeutics Inc (CLDI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
5.38%
자본화:
|
볼륨(24시간):